Altasciences has announced the continued expansion of their formulation, manufacturing and analytical services facilities in Philadelphia, PA. Altasciences, an integrated drug development solution company offering pharmaceutical and biotechnology companies worldwide a flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing and analytical services, launched a second building project to increase its capacity and meet the ever-growing needs of its clients.
 
Altasciences’ first warehouse expansion started earlier this year and is expected to be ready for use by the end of 2021. The 35,000 square foot space, acquired in December 2020, is directly adjacent to Altasciences’ existing facility. The new space, with its 24-foot ceilings, will be configured to include an approximately 8,750 square foot warehouse, a roughly 8,750 square foot Grade C/D manufacturing area and a 17,500 square foot client-dedicated cGMP manufacturing area.
 
In addition, Altasciences has expanded into a new 53,000 square foot client-dedicated facility for formulation development and Phase I through to commercial manufacturing. This new project is expected to be completed in 2023.
 
“Completing these significant expansions and investment into both capacity and state-of-the-art technology will ensure that Altasciences can provide the drug development solutions that our customers need now and in the future,” said Ben Reed, Altasciences’ executive vice president of operations. “Altasciences prides itself on listening to what our clients need, and then adapting to their requirements.”